Biofrontera

Biofrontera Capital Expenditures

The Capital Expenditures (CapEx) of Biofrontera (B8FK.DE) as of Nov 21, 2026 is -51,000.00 EUR. In the previous year, Capital Expenditures (CapEx) was -210,000.00 EUR — a change of -75.71% (higher).

Capital Expenditures

-51,000.00EUR

YoY

-75.71%

Last updated:

Capital Expenditures (CapEx) of Biofrontera is 2025 -51,000.00 EUR. Capital Expenditures (CapEx) of Biofrontera was 2024 -210,000.00 EUR. It decreases by -75.71% higher compared to the previous year.

The Biofrontera Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-513,000.00 EUR
Jan 1, 2019
-1.85 M EUR
Jan 1, 2020
-774,000.00 EUR
Jan 1, 2021
-629,000.00 EUR
Jan 1, 2022
-981,000.00 EUR
Jan 1, 2023
-912,000.00 EUR
Jan 1, 2024
-210,000.00 EUR
Jan 1, 2025
-51,000.00 EUR
The Biofrontera Capital Expenditures history
YEARCapital ExpendituresYoY
-51,000.00EUR-75.71%
-210,000.00EUR-76.97%
-912,000.00EUR-7.03%
-981,000.00EUR+55.96%
-629,000.00EUR-18.73%
-774,000.00EUR-58.25%
-1.85 MEUR+261.40%
-513,000.00EUR+29.22%
-397,000.00EUR-18.07%
-484,537.00EUR+168.73%
-180,303.00EUR+9.89%
-164,082.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Capital Expenditures (CapEx) of Biofrontera is -51,000.00 EUR in 2025.

Capital Expenditures (CapEx) of Biofrontera changed from -210,000.00 EUR to -51,000.00 EUR, representing a -75.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Biofrontera since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Biofrontera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biofrontera

All Key Metrics — Biofrontera